Kymriah market seen growing on CAR-T demand and personalized medicine

The Business Research Company says the global Kymriah market is expanding on stronger clinical adoption, rising blood cancer cases and broader interest in personalized cancer care. North America led the market in 2025, while Asia-Pacific is projected to grow the fastest through 2035.

Why it matters: - Kymriah’s market trajectory points to broader adoption of CAR-T therapies in cancer care. - Rising blood cancer incidence, improved reimbursement, and more treatment-center capacity could expand access to the therapy. - The market outlook matters for drugmakers, cell therapy manufacturers, and providers building specialized cancer programs.

What happened: - The Business Research Company published its Kymriah Global Market Report 2026, covering market size, trends, and a forecast through 2035. - The report says the Kymriah market is gaining attention as cell therapy advances continue to change cancer treatment. - The report includes a free sample download and the full market report at the company’s sample request page and the full report.

The details: - The report says past growth was driven by immuno-oncology research, regulatory approvals for cell therapies, improved outcomes in hard-to-treat cancers, specialized treatment centers, and investment in cell therapy infrastructure. - The forecast period is expected to benefit from more CAR-T indications, higher adoption among adult patients, more automation in manufacturing, cost optimization, and wider reimbursement programs. - Key market trends listed in the report include broader use of CAR-T therapies, personalized cancer treatment strategies, advanced cell processing, data-driven patient monitoring, and scalable manufacturing. - Kymriah is described as a CAR-T cell therapy that modifies a patient’s T cells, engineers them to recognize cancer markers, and reinfuses them to attack cancer cells. - The therapy is aimed primarily at certain blood cancers, including leukemia and lymphoma. - The report links market growth to rising hematological cancers, which affect the blood, bone marrow, lymph nodes, and lymphatic system. - The Leukemia & Lymphoma Society reported in September 2024 that a new U.S. diagnosis of leukemia, lymphoma, or myeloma occurs about every three minutes. - The same source projected about 187,740 new U.S. cases of those blood cancers in 2024. - The report also points to personalized medicine as a growth driver because therapies tailored to genetics, environment, and lifestyle can improve outcomes and reduce side effects. - The Personalized Medicine Coalition noted in February 2024 that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - North America held the largest share of the Kymriah market in 2025. - Asia-Pacific is expected to post the fastest growth over the forecast period. - The report also covers Western Europe, Eastern Europe, South America, the Middle East, and Africa. - New 2026 report features include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The report also adds key technologies and future trend analysis.

Between the lines: - The market story is less about one product and more about the broader shift toward highly customized, high-complexity cancer treatment. - Faster growth in Asia-Pacific suggests demand is broadening beyond the most established CAR-T markets, even as North America remains the largest base. - Manufacturing automation and reimbursement expansion look especially important because CAR-T therapies are costly and operationally complex.

What's next: - Market growth will likely track additional CAR-T indications, payer coverage decisions, and the pace of manufacturing scale-up. - Adoption should also depend on how quickly treatment centers can build the infrastructure needed to deliver cell therapies. - The report’s forecast runs through 2035, giving investors and industry players a long horizon for planning.